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Abstract
Molecular diagnostic techniques for viral testing have undergone rapid development in recent years. They are becoming more widely
used than the classical virological assays in the majority of clinical virology laboratories, and now represent a new method for the diag-
nosis of human viral infections. Recently, new techniques based on multiplex RT-PCR ampliﬁcation followed by microarray analysis have
been developed and evaluated. On the basis of ampliﬁcation of viral genome-speciﬁc fragments by multiplex RT-PCR and their subse-
quent detection via hybridization with microorganism-speciﬁc binding probes on solid surfaces, they allow simultaneous detection and
identiﬁcation of multiple viruses in a single clinical sample. The management of viral central nervous system and respiratory tract infec-
tions currently represents the two main applications of the microarrays in routine virological practice. Microarrays have shown reliable
results in comparison with those of referenced (RT)-PCR assays, and appear to be of major interest for the detection of a broad range
of respiratory and neurotropic viruses, assessment of the pathogenicity of newly discovered or neglected viruses, and identiﬁcation of
multiple viral infections in clinical samples. Despite several limitations observed during the different studies performed, this new technol-
ogy might improve the clinical management of patients by enlarging the range of the viruses detected, in particular in cases of severe
infections leading to patient hospitalization in the intensive-care unit. They might also help in the prevention of nosocomial transmission
in hospital departments by contributing to the development of new epidemiological surveillance systems for viral infections.
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Molecular diagnostic techniques for viral testing have under-
gone rapid development in recent years [1]. They are becom-
ing more widely used than the classical virological assays
(immunoﬂuorescence assay and virus isolation in cell culture)
in the majority of clinical virology laboratories, and now repre-
sent a new method for the diagnosis of human viral infections.
More sensitive and more rapid than traditional methods,
nucleic acid ampliﬁcation tests have also allowed the detection
of a broader panel of viruses in clinical specimens [2–4].
Recently, new techniques based on multiplex RT-PCR ampliﬁ-
cation followed by microarray analysis have been developed
and evaluated in clinical samples [5–8]. Microarrays are divided
into high-density and low-density DNA-probe hybridization
technologies. High-density microarrays can test for thousands
of potential pathogens simultaneously, allowing the detection
of novel or previously uncharacterized agents, but they
are not yet applicable for daily diagnosis in clinical virology
practice. Only low-density microarrays are currently CE-
marked for the in vitro diagnosis of human viral diseases. These
new assays can allow rapid detection and identiﬁcation, includ-
ing typing and subtyping, of a broad panel of common and
newly discovered human viral pathogens. The use of these
microarrays might improve the clinical management of patients
and the prevention of nosocomial transmission in hospital
departments, and might allow the development of new epide-
miological survey systems for viral infections [1,5,8].
Low-density microarray technology is based on ampliﬁca-
tion of viral genome-speciﬁc fragments, of <350 bp, by
multiplex (RT-)PCR, and their subsequent detection via
hybridization with microorganism-speciﬁc binding probes on
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solid surfaces, allowing simultaneous detection and identiﬁca-
tion of multiple viruses in a single clinical sample. In the com-
mercially available microarrays, ampliﬁed products are
labelled with biotin during the ampliﬁcation step. They then
hybridize with their respective speciﬁc probes immobilized in
known sites of the microarray placed at the bottom of a sin-
gle tube or of eight-well strips. Incubation with streptavidin–
peroxidase conjugate reagent leads, in the presence of the
substrate, to the appearance of an insoluble product at the
hybridization sites. Finally, a microarray reader piloted by spe-
ciﬁc software provided by the manufacturer allows the cap-
ture and processing of the picture obtained from the
microarray [5,6,8,9].
The ﬁrst main application of the low-density microarrays
in routine virological practice consisted of the diagnosis of
viral central nervous system (CNS) infections. Viruses are
the main aetiological cause of CNS infections, ahead of bac-
terial and fungal causes [10]. PCR has been recognized as
the reference method for the diagnosis of viral CNS infec-
tions in cerebrospinal ﬂuid (CSF) specimens [11,12]. The
molecular tests used in routine diagnosis have to be speciﬁc
and highly sensitive, allowing rapid and valuable detection of
RNA and DNA viruses. At the present time, the diagnosis of
viral CNS infections is usually obtained through the combina-
tion of multiple PCR and RT-PCR assays, resulting in labora-
tory conﬁrmation of c. 45% of physician-diagnosed cases
[13]. This failure can be explained by the inconsistency
between the small volume of CSF available and the wide
range of viruses potentially responsible for CNS infections,
as well as their genetic characteristics (both DNA and RNA
viruses), which also complicate rapid and large virological
diagnosis using monoplex RT-PCR and PCR assays [14]. The
alternative of a multiplex PCR approach followed by micro-
array analysis allows optimization of the detection of neuro-
tropic viruses. The previously published microarrays showed
concordant results with single endpoint PCR tests used to
assess the reliability of the method [15–17].
Recently, we evaluated the analytical and clinical perfor-
mance of a commercially available multiplex RT-PCR DNA
microarray allowing rapid and simultaneous detection of nine
DNA and RNA neurotropic viruses—herpes simplex virus
type 1, herpes simplex virus type 2, varicella zoster virus,
cytomegalovirus, Epstein–Barr virus, human herpesvirus
type 6, human herpesvirus type 7 (HHV-7), human herpesvi-
rus type 8, and enterovirus (EV)—in a single CSF sample [9].
This evaluation was conducted in a ﬁrst phase by testing pro-
ﬁciency samples of the 2008 and 2009 European proﬁciency
panels (Quality Control for Molecular Diagnostics, Glasgow,
UK) and, in a second phase, by testing 78 CSF specimens
from patients hospitalized for CNS infections that had been
previously tested with standardized commercially available
PCR and RT-PCR assays for neurotropic virus detection. The
microarray demonstrated a limit of detection of <500 copies/
mL for all six herpesviruses tested (no Quality Control for
Molecular Diagnostics available for HHV-7 and human
herpesvirus type 8) and a lower sensitivity of >1000 copies/
mL for EV detection. These results were similar to those
recorded by the participants in the External Quality Assess-
ment programmes, whatever the molecular technique used.
The retrospective analysis of 68 CSF samples that initially
tested positive for either herpesviruses or EV with standard-
ized commercially available RT-PCR and PCR assays con-
ﬁrmed the reliable diagnosis of the CNS infections by the
microarray, as 27 of the 28 herpesvirus-positive samples and
all of the 30 EV-positive CSF samples tested positive. Interest-
ingly, the microarray detected 11 (37%) HHV-7 and EV mixed
infections among the 30 paediatric aseptic meningitis cases
initially related to EV. Detection of HHV-7 was conﬁrmed by
quantitative real-time PCR assay, which demonstrated viral
loads ranging from 60 to 300 genome copies per millilitre of
CSF (mean value = 163 ± 96 copies/mL) [18]. Whereas EVs
are well known neurotropic viruses, HHV-7 infection remains
a neglected topic [19]. Statistical analyses of the demographic,
clinical and therapeutic characteristics revealed that HHV-7
and EV mixed infection caused signiﬁcantly longer lengths of
stay at the hospital for children suffering from aseptic menin-
gitis than for those infected with EV alone. The lack of corre-
lation between HHV-7 detection and CSF leukocyte counts
suggested that the HHV-7 DNA was from actively replicating
virus and not just latent HHV-7 DNA carried in inﬂammatory
cells. Moreover, as the CSF samples had been routinely
submitted to the virology laboratory for neurotropic virus
detection from March 2002 to May 2009, no epidemiological
link suggesting an outbreak of HHV-7 infection can be estab-
lished. These preliminary data led to the question of the role
of HHV-7 as an EV meningitis cofactor associated with
increased severity of the disease. Finally, this ﬁrst description
of combined HHV-7 and EV infection highlighted the advan-
tage of the microarray technology for the detection of mixed
viral CNS infections, as well as for the investigation of the
pathogenicity of neglected viruses [8].
The second main application of microarrays is the manage-
ment of respiratory tract infections (RTIs). We recently con-
ducted two studies aimed at the evaluation of this technology
in the virological diagnosis of RTIs. In the ﬁrst, we prospec-
tively tested nasal swabs or nasopharyngeal aspirates from
adult and paediatric patients visiting the Reims University
Medical Centre (northern France) for inﬂuenza-like illnesses
(ILIs) during the early stage of the French inﬂuenza A/H1N1
2009 pandemic. ILI can be related to A and B inﬂuenza
CMI Le´veˆque et al. Microarray technology in clinical virology 11
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 10–14
viruses, including inﬂuenza A/H1N1 2009, but also to a large
number of respiratory viruses [20]. Therefore, rapid and reli-
able screening of a large panel of respiratory viruses responsi-
ble for ILI is of major epidemiological and clinical interest for
monitoring an inﬂuenza pandemic wave [21].
Ninety-ﬁve respiratory samples collected in October 2009
were tested with a combination of two commercially avail-
able microarrays allowing rapid detection of inﬂuenza A virus
strains, including the new A/H1N1 2009 strain and 20 other
respiratory viruses [8]. Viruses were detected in 65 (68.4%)
of the 95 respiratory samples tested with the microarrays, in
agreement with the results of real-time RT-PCR assays [8].
Inﬂuenza A/H1N1 2009 was detected in only 30 (31%) sam-
ples, whereas rhinoviruses and parainﬂuenza viruses were
important causes of ILI, with 25% and 10.5% prevalence,
respectively. Moreover, the use of the microarrays revealed
ten (10.5%) mixed infections, mainly inﬂuenza A/H1N1 2009
with coronavirus, human bocavirus (HBoV), human respira-
tory syncytial virus (hRSV), or human rhinoviruses (HRVs).
The microarray technology thus appeared to be of major
interest in clinical virology practice for rapid and accurate
diagnosis of patients suffering from ILIs, which can be caused
by a large range of respiratory viruses.
In the second study, the application of microarrays was
assessed in the diagnosis and the epidemiological survey of
viral infections in infants hospitalized for bronchiolitis. Bron-
chiolitis is an important manifestation of viral RTIs, and a large
variety of viral pathogens, most notably hRSV, are implicated
in the majority of hospitalized cases, with variable contribu-
tions from HRVs, Adenovirus (AdVs), human metapneumovi-
rus A (hMPV-A), human metapneumovirus B (hMPV-B),
inﬂuenza virus type A, inﬂuenza virus type B, parainﬂuenza
virus type 1, parainﬂuenza virus type 2, and parainﬂuenza
virus type 3 (PIV3) [22,23]. In addition, non-conventional
pathogens (emerging or newly identiﬁed), such as the coro-
naviruses E-229, NL63 and HKU1, HRV-C and HBoV, have
been associated with severe acute bronchiolitis cases [22–24].
One hundred and thirty-eight nasopharyngeal aspirates col-
lected from October 2007 to September 2008 were tested
by direct immunoﬂuorescence and viral culture, a combina-
tion of referenced RT-PCRs, and a commercially available
microarray allowing rapid and simultaneous detection of 17
DNA and RNA human respiratory viruses [6]. One or more
viruses were detected in 126 (91%) of the specimens with
the microarray, and similar results were obtained with refer-
enced (RT)-PCR assays [6]. As expected, the global detection
rate appeared to be higher with the microarray than with
classical techniques (direct immunoﬂuorescence and virus
isolation) (91% vs. 70%, p <10)3), even for common respira-
tory viruses such as hRSV-A/B. Microarray analysis conﬁrmed
that hRSV-A (52%), hRSV-B (40%), HBoV (27%), AdVs (22%),
PIV3 (15%), hMPV-A, hMPV-B (12%) and HRVs (8%) are
the most frequently detected viruses in bronchiolitis cases
[21–25]. The microarray also identiﬁed 85 (67%) mixed RTIs,
whereas none was detected with the classical techniques.
The most common associations were hRSV-A/B with HBoV
(32%), hRSV-A/B with AdVs (30%), and hRSV-A/B with PIV3
(23%). Furthermore, the screening of clinical specimens with
the microarray appeared to be of major epidemiological
interest for monitoring the circulation of viruses responsible
for bronchiolitis in hospitalized infants. In addition to the clas-
sical epidemic circulation of hRSV-A/B during the winter
season, the microarray showed concomitant epidemic circu-
lation of AdVs, PIV3, HBoV, hMPV-A/B, HRVs and EV result-
ing in the majority of the mixed RTIs detected. Moreover,
the epidemiological survey conducted over a period of 1 year
showed a spring peak of HBoV infections that was not
detected by use of the conventional techniques. With the
results obtained by the microarray, the inﬂuence of the virus
species and the impact of mixed viral infections on bronchio-
litis severity were analysed. Statistical analyses revealed that
none of the bronchiolitis severity criteria, including intensive-
care unit admission, O2 supply, O2 saturation percentage, O2
length, and length of stay at the hospital, was signiﬁcantly
increased in cases of mixed infections as compared with sin-
gle infections, and that no speciﬁc viral combination was asso-
ciated with the severity of the disease. Only infants infected
with hRSV stayed longer in hospital [24]. However, given the
large panel of multiple viral infections detected by the micro-
array, further multicentre studies will be necessary to assess
whether speciﬁc viral associations could confer an elevated
risk of severe bronchiolitis.
Regarding the practical aspects, the analyses performed
with the microarrays could be performed with 5–10 lL of
total nucleic acid extract obtained from a same aliquot of
the clinical specimens. With the kits that we evaluated, the
running time for ampliﬁcation of multiplex RT-PCRs was
3.30 h, and the time needed for hybridization of PCR prod-
ucts was 3 h. Microarray scanning and analysis were carried
out within 15 min. In summary, the total time needed to
complete the assay was c. 8 h from specimen extraction to
microarray detection, allowing the laboratory to provide the
answer to the clinician in a single working day. Moreover,
for each sample analysed, the accuracy of the microarray
analysis was controlled during extraction and ampliﬁcation
through an internal control, and during hybridization with at
least three probes per ampliﬁed target detected.
Several limitations of the microarrays were observed dur-
ing the different studies performed. Numerous handling steps
were required during the analysis, and opportunities for
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automation remained limited. Moreover, the commercially
available microarrays cannot be used without a microarray
reader piloted by speciﬁc software provided by the manufac-
turers, limiting the implementation of the kits in virology
laboratories. By comparison with the one-step real-time PCR
assays frequently used in current molecular virological
diagnosis, the major drawback of the technique was the han-
dling of amplicons. Although no contamination event was
observed during these evaluations, a potential risk of con-
tamination could not be ruled out. Finally, microarray tech-
nology, which is a multiplex endpoint PCR system, did not
allow quantitation of the viral load in the clinical samples. It
has been assumed that quantitation of viral nucleic acid in
CSF samples may be useful in monitoring the effectiveness of
antiviral therapy, and for establishing the prognosis of CNS
infections [26–28]. Moreover, although the diagnostic value
of the viral load in the nasopharyngeal aspirates remains
unclear, the quantiﬁcation of respiratory viruses may provide
important information about the inﬂuence of the viral load
on disease severity and the role of viral pathogens in single
or multiple RTIs [29]. Hence, in cases of mixed viral RTIs,
speciﬁcally with viruses not detectable by classical tech-
niques, it was not possible to determine which virus was
predominant and could be considered as the aetiological
agent or to demonstrate whether the virus detection could
be linked to beginning, ongoing or past viral RTIs [29,30].
The place of this new technology in virology laboratories
could vary according to the aims of the analyses performed.
In routine virology practice, these assays should be consid-
ered as third-line tests, after rapid antigen tests (RATs) and
monoplex (RT)-PCR assays, to enlarge the range of the
viruses detected, in particular in cases of severe infection
leading to patient hospitalization in the intensive-care unit
(Fig. 1A). Another possibility could be to use them directly
after the RAT, in order to conﬁrm the ﬁrst positive results
obtained or, in cases of negative results with the RAT, to per-
form an enlarged virological screen in the same clinical sample
(Fig. 1B). Finally, microarrays could be used as ﬁrst-line tests
for the detection of viral pathogens; this last possibility, which
does not provide rapid and cost-efﬁcient results to the
physicians, should be limited to national centres for infectious
diseases control as part of epidemiological surveys (Fig. 1C).
In conclusion, microarrays currently allow rapid and reli-
able detection of a broad range of respiratory and neuro-
tropic viruses, as well as the identiﬁcation of single and
multiple viral infections in clinical samples. Despite the lack
of virus quantitation, they provide rapid typing and subtyping
of viral strains that can be useful in both clinical practice and
epidemiological surveys.
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